# Rosai-Dorfman Disease Presenting as a Bone-Destructive Mass in the Maxillary Sinus With Orbital Extension: A Diagnostic and Therapeutic Challenge

**Authors:** Miki Junicho, Akira Nakazato, Hirohiko Tachino, Yuka Morita

PMC · DOI: 10.7759/cureus.85870 · Cureus · 2025-06-12

## TL;DR

A rare case of Rosai-Dorfman disease in the maxillary sinus was successfully treated with corticosteroids, avoiding unnecessary aggressive treatment.

## Contribution

This case report highlights the diagnostic challenge of RDD in the maxillary sinus and demonstrates the effectiveness of corticosteroid therapy.

## Key findings

- RDD can present as a bone-destructive mass in the maxillary sinus with orbital extension, mimicking malignancy.
- Histopathology confirmed RDD with characteristic S-100- and CD68-positive histiocytes and emperipolesis.
- Oral corticosteroids led to rapid symptom resolution and no recurrence over 18 months.

## Abstract

Rosai-Dorfman disease (RDD) is a rare histiocytic disorder characterized by massive lymphadenopathy and, in some cases, extranodal involvement, resulting in significant functional impairment. Maxillary sinus lesions with orbital extension are extremely rare and may mimic malignancy. We report the case of a 76-year-old man who presented with left lower eyelid swelling and diplopia. Computed tomography revealed a mass centered in the left maxillary sinus, extending into the orbit and buccal subcutaneous tissue, accompanied by osteolytic changes. Serologic testing, including soluble interleukin-2 receptor (sIL-2R) and immunoglobulin G4 (IgG4) level, was unremarkable. An initial nasal biopsy suggested chronic inflammation; however, surgical excision was performed due to concerns about malignancy. Histopathology revealed S-100- and CD68-positive histiocytes exhibiting emperipolesis, confirming a diagnosis of RDD. The patient was treated with oral corticosteroids (prednisolone 1 mg/kg/day), resulting in rapid symptom resolution without recurrence over an 18-month follow-up period. This case highlights the importance of including RDD in the differential diagnosis of bone-destructive maxillary sinus lesions. Although RDD is not a malignant tumor, it can cause significant functional impairment. Corticosteroids appear to be an effective treatment option. Early diagnosis and appropriate steroid therapy may lead to excellent outcomes while avoiding overtreatment.

## Linked entities

- **Proteins:** S100A1 (S100 calcium binding protein A1), CD68 (CD68 molecule)
- **Chemicals:** prednisolone (PubChem CID 5755)
- **Diseases:** Rosai-Dorfman disease (MONDO:0006412), malignancy (MONDO:0004992)

## Full-text entities

- **Genes:** S100A1 (S100 calcium binding protein A1) [NCBI Gene 6271] {aka S100, S100-alpha, S100A}, CD68 (CD68 molecule) [NCBI Gene 968] {aka GP110, LAMP4, SCARD1}
- **Diseases:** malignancy (MESH:D009369), RDD (MESH:D015618), Maxillary sinus lesions (MESH:D008444), lymphadenopathy (MESH:D008206), histiocytic disorder (MESH:D015620), inflammation (MESH:D007249), lower eyelid swelling (MESH:D005141), diplopia (MESH:D004172)
- **Chemicals:** steroid (MESH:D013256), prednisolone (MESH:D011239)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12255481/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12255481/full.md

## References

11 references — full list in the complete paper: https://tomesphere.com/paper/PMC12255481/full.md

---
Source: https://tomesphere.com/paper/PMC12255481